Skip to main content

Search

Reset all filters
234 Result(s)
Sort by

Angels Initiative in South Africa

Angels Initiative in South Africa

Dr Stacey Rossouw explains how the Angels initiative is making a difference in South Africa and optimizing stroke care
Thelaziosis dog eyeworms

Thelaziosis dog eyeworms

Have you heard of Thelaziosis? In Europe, some fruit flies host an emerging parasite known as “eyeworm”, an infestation which causes more or less severe conjunctivitis, sometimes leading to corneal ulcers and even blindness in dogs.
Geographic Atrophy

Geographic Atrophy

Geographic Atrophy is a slowly progressing, yet damaging form of AMD. Approximately 5 million people have Geographic Atrophy worldwide, with disease prevalence increasing with age. It is characterized by regions of cell death in the retina.
Advancing regenerative medicine

Advancing regenerative medicine

Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
Stroke Risk Factors Symptoms

Stroke Risk Factors Symptoms

Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. There is a simple test that can help everyone identify the most common symptoms of a stroke.
Taking cancer on with smart combinations

Taking cancer on with smart combinations

Boehringer Ingelheim digs deep into the science and taking a precision approach to develop smart combinations to bring the greatest benefit to patients.
Targeting Tumor Stroma

Targeting Tumor Stroma

Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
Meet BIs Brains Michael Sand

Meet BIs Brains Michael Sand

Dr. Michael Sand, Senior Clinical Program Leader, CNS at Boehringer Ingelheim shares his view on the complexities of the CNS research landscape.
COVID-19 Ivermectin Animal Health Not for Human Use

COVID-19 Ivermectin Animal Health Not for Human Use

Boehringer Ingelheim manufactures several veterinary products containing ivermectin. They are not approved or suitable for use in humans to try to prevent or treat COVID-19.
Partnering Vanderbilt WCNDD

Partnering Vanderbilt WCNDD

Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
BI Access to Healthcare Strategy_Availability

BI Access to Healthcare Strategy_Availability

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Our Innovation Strategy

Our Innovation Strategy

Our discovery research strategy is designed to sustain our track record of innovation and look for new and breakthrough medicines.